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Abstract  Interventional  oncology  is  developing  rapidly  as  a  result  of  advances  in  imaging  and
medical devices.  Although  the  treatments  offered  are  recent  and  not  yet  fully  validated  in
the guidelines,  they  allow  non-invasive  curative  treatments  to  be  offered  to  a  growing  num-
ber of  patients.  When  it  is  used  in  a  highly  selected  patients  with  less  than  three  metastases
under 2—3  cm  in  size,  percutaneous  tumor  ablation  offers  local  efﬁcacy  similar  to  excision
surgery with  considerable  sparing  of  the  parenchyma,  both  for  lung  and  liver  metastases.  Hep-
atic intra-arterial  therapies  (chemotherapy,  radioembolization,  and  chemoembolization)  are
now ‘‘salvage’’  methods  after  chemotherapy  has  failed  and  are  being  assessed  in  earlier  lines
of treatment.
© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Interventional  oncology  (interventional  radiology  to  treat  cancer)  is  a  rapidly  advancing
specialty  and  in  the  near  future  will  probably  represent  the  fourth  pillar  of  cancer  care
alongside  medical  oncology,  surgery  and  radiotherapy.  Interventional  oncology  allows  new
image-guided  treatments,  which  are  relatively  non-invasive  to  treat  localized  malignant
disease  through  a  potent  local  treatment  effect  (drug  concentration,  thermal  damage),
at  the  same  time  reducing  potential  side  effects,  either  in  the  same  organ  or  remotely.
Local  malignant  disease  is  increasingly  being  found  because  of  early  detection,  routine
monitoring  of  patients  with  known  cancer  and  the  large  reduction  in  tumor  volumes  as  a
result  of  new  classes  of  systemic  therapies.
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For  colorectal  cancer,  interventional  oncology  has  a
ajor  role  for  the  treatment  of  metastatic  liver  and  lung
isease  through  percutaneous  tumor  destruction,  and  in
etastatic  liver  disease  with  intra-arterial  treatments.
ercutaneous ablation
rinciple
ercutaneous  ablation  is  based  primarily  on  thermal  destruc-
ion,  exposing  the  targeted  tumor  cells  to  temperatures
f  over  +60 ◦C  [1]  or  less  than  −40 ◦C  [2]  causing  near-
mmediate  irreversible  cell  death.  The  ﬁrst  thermal  ablation
echnique  to  be  used  was  radiofrequency  ablation  (RFA)
n  which  tissues  are  heated  with  a  sinusoidal  current  (400
o  500  KHz)  by  ionic  friction  from  electrodes  inserted  into
he  tissue.  Other  thermal  ablation  technologies  such  as
icrowave  and  cryoablation  have  been  developed  more
ecently  for  percutaneous  use,  in  an  attempt  to  circumvent
he  limitations  of  RFA  by  ﬁrstly  increasing  ablation  size  using
ifferent  energies  and  the  possible  use  of  several  simultane-
us  applicators,  and  secondly  by  providing  faster  treatment,
nd  reducing  the  sensitivity  of  ablation  to  thermal  conven-
ion,  particularly  in  contact  with  large  diameter  vessels
3,4].  Some  techniques  also  provide  for  more  straightfor-
ard  follow-up  imaging  [5].  The  advantages  of  these  new
echnologies  have  been  demonstrated  in  preclinical  studies
ut  need  to  be  conﬁrmed  in  clinical  trials.  A  non-thermal
estruction  method,  irreversible  electroporation  (IRE)  has
lso  recently  been  introduced  [6]  and  is  currently  under
arly  stage  clinical  assessment  for  the  liver  and  other  organs
7,8].  At  present,  RFA  remains  the  reference  technique  for
ercutaneous  ablation  as  it  is  a  mature  technique  with  many
eported  publications.  As  a  result,  only  the  RFA  results  will
e  considered  below.
iver metastases
he  main  factor  inﬂuencing  the  results  of  thermal  ablation  is
he  size  of  the  target  metastasis  and  there  is  hard  evidence
hat  better  results  are  achieved  after  RFA  for  metastases  of
3  cm  in  size.  The  incomplete  ablation  rate  in  a  now  old  pub-
ication  was  21.6%  for  the  37  metastases  ≥30  mm,  compared
o  2.6%  for  190  metastases  <30  mm  [9].  More  recently,  9,
6.5  and  45%  incomplete  ablation  rates  have  been  reported
or  290  liver  metastases  from  colorectal  cancer  treated  by
FA,  measuring  0—3,  3—5  and  >5  cm,  in  size  respectively
10].  The  risk  of  incomplete  ablation  increases  by  22%  for
ach  5  mm  increase  in  diameter  of  the  tumor  and  falls  by  46%
or  each  5  mm  increase  in  the  depth  of  the  ablation  margin
11].  Apart  from  size,  the  blocks  to  complete  ablation  are
roximity  to  large  vessels,  as  the  ﬂuid  passing  through  the
eated  tissue  causes  cooling  through  convention,  which  is
esponsible  for  the  ‘‘heat  sink  effect’’,  and  causes  difﬁcul-
ies  in  ablating  tissue  close  to  vessels  which  are  3  mm  or
ver  in  diameter  [12—14].  The  incomplete  treatment  rate
or  metastases  close  to  vessels  of  ≥3  mm  has  been  reported
o  be  23%  compared  to  3%  for  metastases  remote  from  these
essels  [9].  This  difference  disappears  with  percutaneous
alloon  occlusion  of  the  vessel  involved  [15].  The  local  efﬁ-
acy  of  RFA  has  been  reported  to  be  equivalent  to  that  of
a
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typical  excision  for  small  metastases,  with  incomplete  local
reatment  rates  of  5.7  and  7.1%  for  227  RFA  and  99  atypical
xcisions,  respectively  [9]. Analysis  of  two  EORTC  studies
n  RFA  in  the  CLOCC  trial  [16]  and  excision  of  metastases
4  cm  in  the  EPOC  trial  [17], reported  a  local  recurrence
ate  of  5.5%  compared  to  6.0%  as  a  result  of  metastases
nd  7.4%  compared  to  14.5%  per  patient  for  excision  and
FA  respectively,  leaving  patients  with  more  advanced  dis-
ase  in  the  RFA  group  [18]  The  local  recurrence  rate  after
FA  for  30  mm  or  smaller  metastases  was  2.9%  (21.4%  for
etastases  over  30  mm)  and  6.2%  after  excision  of  30  mm  or
maller  metastases  [18].  The  local  recurrence  rate  after  RFA
s  considerably  higher  than  after  surgery  for  20  mm  or  larger
umors,  whereas  no  signiﬁcant  difference  is  seen  for  tumors
nder  20  mm  in  size  [19]. The  recurrence  rate  in  patients
ho  had  previously  undergone  hepatectomy  is  reported  as
8%  for  metastases  with  an  average  diameter  of  2.3  cm,
ncluding  6%  for  metastases  ≤3  cm,  and  52%  for  metastases
3  cm  [20].  The  hepatic  recurrence  rate  in  6025  patients
ndergoing  surgery  with  or  without  radiofrequency  ablation
or  malignant  liver  metastases  from  colorectal  cancer  was
5.4%,  including  9.6,  12  and  18.3%  early  recurrence  after
natomical  resection,  atypical  resection  and  RFA  respec-
ively.  Only  anatomical  excision  was  better  than  RFA  and  no
igniﬁcant  difference  was  found  between  RFA  and  atypical
esection.  In  addition  no  difference  in  survival  was  found
etween  the  anatomical  excision,  RFA  and  atypical  resec-
ion  groups  [21]. An  important  factor  for  successful  ablation
hich  is  rarely  reported  is  good  visualization  of  the  target
umor.  Sofocleous  et  al.  reported  a  94%  complete  ablation
ate  (67/71)  for  liver  metastases  from  colorectal  cancer
eveloping  in  the  residual  liver  after  hepatectomy;  three
f  the  four  failures  were  attributed  to  poor  visualization  of
he  tumor,  resulting  in  suboptimal  targeting  [22].
No  randomized  studies  have  compared  surgery  to  ther-
al  ablation  and  the  available  series  are  retrospective  and
ontain  obvious  bias,  comparing  surgery  in  candidates  for
urgery  and  thermal  ablation  in  patients  not  candidates  for
urgery  [23,24],  although  after  stratifying  by  extra-hepatic
xtension,  general  health  and  extent  of  advancement  of  the
isease,  this  difference  usually  disappears  [24].  This  bias  is
ighlighted  in  the  conclusions  of  a  Cochrane  meta-analysis:
‘The  imbalance  between  characteristics  of  patients  in
he  allocated  groups  appears  to  be  the  main  concern’’
25,26].  Patients  who  are  not  candidates  for  surgery  are
enerally  not  the  ideal  candidates  for  thermal  ablation
ither,  as  the  factors  which  make  a  tumor  inoperable  (size,
roximity  to  major  blood  vessels  or  biliary  tract)  also  make
t  difﬁcult  to  treat  with  percutaneous  ablation  and  RFA  is
herefore  usually  reserved  for  patients  who  are  potential
urgery  candidates  but  cannot  have  surgery  because  of
omorbidities  or  if  the  malignant  disease  is  deemed  to
e  too  aggressive  (extra-hepatic  disease,  recurrence  after
urgery,  etc.).  These  selection  bias  issues  impact  on  overall
urvival  with  median  and  5-year  survival  rates  of  4.3  years
nd  48.7%  after  RFA  in  64  technically  operable  patients,
ompared  to  2.2  years  and  18.4%  in  37  RFA  in  137  patients
ho  were  technically  inoperable  [27]. Otto  et  al.  reported
hat  only  a  small  subset  of  candidates  to  surgery  are
menable  to  RFA  [28]. A  retrospective  review  has  examined
123  cases  of  surgery  for  liver  metastases  from  colorectal
ancer  and  compared  141  patients  treated  with  bilateral
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IInterventional  oncology  for  liver  and  lung  metastases  from  c
surgical  excision  to  95  patients  treated  with  thermal
ablation  [thermal  ablation  only  (n  =  9);  thermal  ablation
combined  with  excision  (n  =  86)]  and  reported  an  overall
5-year  survival  rate  of  56%  for  ablation  and  49%  for  excision
(P  =  0.16),  despite  a  higher  clinical  risk  score  (lymph  node
invasion,  disease  free  interval  (DFI)  signiﬁcantly  number
and  size  of  metastases,  CEA  level)  in  the  thermal  ablation
group  [29].  The  use  of  preoperative  RFA  as  a  compliment
to  surgery  in  15%  of  168  surgical  cases  [30]  and  24  of  174
surgical  cases  [31]  was  not  associated  with  reduced  overall
survival  compared  to  surgery  without  ablation.
Ideally  the  comparison  between  surgery  and  RFA  should
include  prognostic  indicators  for  surgery  (stage  of  the  pri-
mary  cancer,  DFI  and  number  and  size  of  metastases,  lymph
node  invasion,  CEA,  age,  excision  margin,  response  to  and
number  of  lines  of  chemotherapy)  [32—34]  and  prognos-
tic  indicators  for  RFA  (lymph  node  invasion  at  the  time  of
surgery  for  the  primary  cancer,  DFI  and  number  and  size  of
metastases)  which  when  combined  into  a  prognostic  score
separates  patients  with  a  2-year  survival  after  RFA  of  74%
compared  to  42%  [18,22].
Apart  from  RFA  in  potential  candidates  for  surgery,  the
role  of  RFA  in  a  more  palliative  situation  needs  to  be  exam-
ined.  There  is  currently  only  one  study,  which  describes
randomization  of  120  patients  between  RFA  combined  with
systemic  chemotherapy  compared  to  chemotherapy  alone  in
patients  with  inoperable  colorectal  liver  metastases.
Progression-free  survival  at  3  years  was  27%  in  the  RFA
plus  chemotherapy  group  and  was  signiﬁcantly  higher  than
the  10.6%  ﬁgure  for  the  chemotherapy  alone  group.  Over-
all  mortality  at  30  months  was  not  signiﬁcantly  different
between  the  groups  although  the  survival  curves  continued
to  separate  over  longer-term  follow-up,  with  overall  survival
rates  of  47%  compared  to  36%  at  4  years  and  40%  compared
to  30%  at  5  years  [16].
Lung metastases
Organ  speciﬁc  differences  favoring  RFA  are  seen  for  the
lung.  Firstly,  the  same  amount  of  energy  produces  a  larger
ablation  volume  in  lungs  than  in  soft  tissues  and  kidneys,
probably  because  of  the  thermal  and  electrical  insulation
provided  by  the  air-ﬁlled  lung  parenchyma  surrounding  the
targeted  metastasis  [35].  Secondly,  pulmonary  RFA  is  always
performed  under  CT  guidance,  which  provides  excellent
visualization  because  of  the  large  differences  in  density
between  the  metal  of  the  needle,  the  metastatic  tissue  and
the  air-ﬁlled  lung,  and  by  the  accurate  targeting  which  can
be  optimally  assessed  on  multiplanar  reconstructions.  This
accurate  targeting  is  essential  for  good  treatment  results.
The  local  efﬁcacy  of  RFA  in  treating  lung  metastases  has
been  proven  with  a  100%  histological  necrosis  rate  in  10  of
the  10  metastases  treated  by  RFA  and  then  excised  surgically
[36].
The  largest  series  published  to  date  included  566  consec-
utive  patients  with  1037  lung  metastases  of  colonic  (34%),
rectal  (18%),  renal  (12%),  sarcomatous  (9%)  or  other  (28%)
origins.  Overall  survival  was  62  months  and  the  3-  and  5-
year  survival  rates  were  67.7%  and  51.5%  respectively  [37].
The  disease  variables  which  were  associated  with  overall
survival  in  a  multivariate  analysis  were  the  site  of  the  pri-
mary  cancer  other  than  colon  or  kidney,  DFI  of  <1  year,  size
H
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2  cm  and  number  of  metastases  >3.  Local  tumor  progres-
ion  at  the  RFA  site  was  also  associated  with  shorter  survival
37]. Earlier  series  showed  slightly  longer  overall  survival  of
1  months  in  148  patients  [38],  41  months  in  122  patients
39]  and  34.9  months  in  84  patients  [40].  The  better  results
n  the  Bergonié/Gustave-Roussy  series  can  be  explained  by
estricted  inclusion  criteria  resulting  in  a  population  with
etter  predictive  indicators  such  as  a median  diameter  of
etastases  of  15  mm,  whereas  the  tumors  were  over  40  mm
n  diameter  in  40%  of  the  cases  reported  by  Chua  et  al.
38]  and  were  up  to  90  mm  in  size  (mean  ±  standard  devi-
tion  =  23  ±  14  mm)  for  Hamada  et  al.  [40]. In  addition,  the
verage  number  of  metastases  present  per  patient  was  1.8
or  de  Baere  et  al.,  compared  to  3.3  for  Gillams  et  al.  [39].
wenty-one  percent  of  the  patients  in  the  series  of  de  Baere
t  al.  also  had  a  DFI  of  under  12  months  [37],  compared  to
2  and  52%  for  Chua  et  al.  and  Gillams  et  al.,  respectively
38,39].
The  5-year  survival  rate  of  51%  with  a  median  overall  sur-
ival  of  62  months  reported  for  RFA  compares  well  with  the
est  results  reported  for  surgery  for  lung  metastases.  These
escribe  a  5-year  survival  rate  of  53.5%  and  median  survival
f  69.5  months  in  a  multicenter  register  of  lung  metastasec-
omies  from  colorectal  cancer  [41],  a  5-year  survival  rate  of
7%  to  68%  and  overall  survival  of  33  to  72  months  in  a  meta-
nalysis  [42], and  a  5-year  survival  rate  of  32.7%  to  56%  and
verall  survival  of  37  to  47  months  in  a  literature  review
f  11  publications  which  included  1307  patients,  and  also
eported  a  5-year  survival  rate  of  39.1  to  67.8%  for  R0  resec-
ion  [43].  The  predictive  indicators  for  overall  survival  after
FA  described  above  are  similar  to  those  for  lung  metasta-
ectomies  and  are  the  origin  of  the  primary  cancer,  number
f  metastases,  R0  resection,  pre-resection  ACE  level  and
istological  lymph  node  invasion  [41,42,44]. The  use  of  mini-
nvasive  techniques  for  local  treatment  of  lung  metastases  is
ot  associated  with  differences  in  local  recurrence  or  over-
ll  survival  [45], although  obviously  RFA  does  not  provide
egional  control  of  the  disease  and  speciﬁcally  does  not  pro-
ide  control  of  lymph  nodes.  The  possible  beneﬁt  of  surgical
ymphadenectomy,  however,  is  not  proven  [46,47]  and  curet-
age  is  usually  not  performed  in  lung  metastasectomies.  RFA
or  lung  metastases  can  be  repeated  if  needed.  As  it  is  rela-
ively  non-invasive  and  spares  the  healthy  lung  parenchyma,
f  changes  in  respiratory  function  are  not  present  after  RFA
48,49],  24%  of  patients  treated  initially  can  be  retreated
ith  RFA  up  to  4  times,  with  a  44.1%  control  rate  reported
or  metastatic  lung  disease  at  4  years  compared  to  a  4-year
FS  rate  before  repeat  treatment  of  20.3%  [37].
RFA  for  lung  metastases  is  a treatment  option  for  metas-
ases  under  2—3  cm  in  diameter  and  is  widely  used  in
atients  who  are  not  candidates  for  surgery,  or  if  surgery
equires  extensive  resection.  RFA  for  lung  metastases  in  can-
idates  for  surgical  candidates  is  an  option  which  needs  to  be
iscussed  in  a  multidisciplinary  team  meeting,  as  its  results
re  superimposable  on  those  of  surgery  itself.
ntra-arterial treatmentsepatic  intra-arterial  treatment  beneﬁts  from  the  fact  that
iver  tumors  are  preferentially  and  almost  exclusively  sup-
lied  by  the  hepatic  artery,  whereas  the  healthy  liver
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arenchyma  is  vascularized  30%  from  the  hepatic  arterial
ystem  and  70%  from  the  portal  system.
Hepatic  intra-arterial  chemotherapy  (HIAC)  initially  used
-FU  and  FUDR  because  of  the  high  liver  extraction  rates,
f  19—51%  and  94—99%,  respectively  [50].  Many  randomized
rials  with  these  drugs  have  reported  better  response  to  HIAC
han  IV  therapy,  although  only  two  studies  have  shown  a
eneﬁt  on  survival  with  HIAC  [51,52],  probably  because  most
f  the  trials  allowed  crossover  and  the  actual  numbers  of
IAC  performed  were  low.
More  recently,  combined  HIAC  and  FUDR  with  oxaliplatin
nd  systemic  irinotecan  achieved  an  objective  response  rate
f  90%  and  a  47%  conversion  rate  to  surgery  in  initially
noperable  patients  [53].  HIAC  with  oxaliplatin  achieved  an
verall  response  rate  of  62%  and  a  20%  conversion  rate  to
urgery  in  patients  who  had  already  been  extensively  treated
ith  systemic  therapies  and  had  already  received  oxaliplatin
n  =  34),  irinotecan  (n  =  37)  or  both  agents  (n  =  28)  [54].  Used
rst  line,  HIAC  with  oxaliplatin  combined  with  systemic  5-FU
nd  cetuximab  achieved  a  90%  objective  response  rate,  100%
ontrol  of  the  disease  and  time  to  progression  of  20  months
ith  a  48%  surgical  conversion  rate  [55].  It  should  be  noted
hat  the  magnitude  of  the  response  and  complete  pathologi-
al  response  rate  (conﬁrmed  on  surgical  excision)  increased
y  a  factor  of  9.33  (1.59—54.7)  when  oxaliplatin  was  given
ntra-arterially  compared  to  systemically  [56].  In  the  same
tudy,  the  complete  disease  response  was  associated  with
n  increase  in  overall  survival  of  114  months  compared  to
2  months.
The  precise  role  of  HIAC  in  inoperable  liver  metastases
s  still  being  debated  between  ﬁrst  line  therapy,  inten-
iﬁcation  after  a  poor  response  to  ﬁrst  line  therapy  and
alvage  or  adjuvant  treatment  [57,58],  although  its  feasibil-
ty  has  considerably  increased  as  a  result  of  the  possibility
f  percutaneous  implantation  of  catheters  and  ports,  provid-
ng  permanent  access  to  the  hepatic  artery.  The  technical
uccess  rate  of  percutaneous  insertion  through  a  femoral
pproach  is  94  to  99%  [59—61].  A  comparison  of  percuta-
eous  and  surgical  approaches  showed  equivalent  primary
atency  (4.80  courses  compared  to  4.82  courses)  with  higher
econdary  patency  rates  after  repeat  percutaneous  inter-
ention  with  percutaneous  implantation  (9.18  compared  to
.95  courses,  P  =  0.004)  [59,62].  The  migration  and  obstruc-
ion  rates  for  catheters  implanted  percutaneously  are  in  the
egion  of  3  to  10%,  with  a  30%  extra-hepatic  infusion  rate
equiring  regular  imaging  monitoring  of  catheter  function.
epeat  percutaneous  procedures  are  performed  if  necessary
ither  to  obstruct  an  extra-hepatic  artery  or  for  ﬁbrinolysis
f  a  partially  obstructed  catheter  or  to  change  a  completely
bstructive  catheter  [63].  Only  obstruction  of  the  hepatic
rtery,  a  very  rare  event,  is  usually  irreversible.  Overall  the
IAC  dropout  rate  due  to  malfunction  of  the  chamber/port
ystem  is  21%  after  percutaneous  implantation  and  34%  after
urgical  implantation  [64],  casting  some  doubt  on  surgical
mplantation,  even  if  the  surgery  itself  is  performed  for
ther  reasons  [65].
Chemoembolization  has  recently  been  examined  in  col-
rectal  metastases  using  drug  elution  beads  laden  with
rinotecan  (DEBIRI).  In  preclinical  studies,  DEBIRI  improved
he  pharmacokinetics  of  irinotecan  with  27,  18.3  and
74.4  ng  of  irinotecan  per  200  mg  of  tumor,  24  hours  after
V,  HIAC  and  DEBIRI  injection  of  irinotecan  respectively  [66],
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0%  of  the  irinotecan  being  released  in  the  ﬁrst  hour  and  98%
fter  2  hours  [67].  One  study  on  55  patients  who  had  failed
rst  line  treatment  with  FOLFOX-bevacizumab  (n  =  55),  sec-
nd  line  therapy  with  FOLFIRI-cetuximab  (n  =  14)  and  third
ine  therapy  (n  =  24),  reported  a  75%  objective  response
ate  at  12  months  with  overall  survival  of  19  months  and
ime  to  progression  after  DEBIRI  of  11  months  [68].  A  ran-
omized  study  on  74  patients  which  compared  DEBIRI  and
OLFIRI  IV  reported  a long  overall  survival  with  DEBIRI  of
2  months  (95%  conﬁdence  interval  (CI)  =  21—23)  for  DEBIRI
nd  15  months  (95%  CI  =  12—18)  for  FOLFIRI  [69]. The  times
o  progression-free  survivals  were  7  months  (95%  CI  =  3—11)
or  DEBIRI  compared  to  4  months  (95%  CI  =  3—5)  for  FOLFIRI
P  =  0.006,  log-rank).  Early  toxicity  was  greater  with  DEBIRI
70%)  compared  to  FOLFIRI  (25%)  and  late  toxicity  was  higher
ith  FOLFIRI  (80%)  than  DEBIRI  (20%).  The  toxicity  proﬁles  of
EBIRI  and  FOLFIRI  were  different,  with  grade  3  neutrope-
ia  in  4  and  44%  of  cases,  diarrhea  in  6  and  18%  of  cases  and
ucitis  in  1  and  20%  of  cases  respectively.  The  costs  of  DEBIRI
ere  signiﬁcantly  lower  than  those  of  FOLFIRI  (D  8000  for
wo  courses  compared  to  D  26,000  for  8  courses).
Radioembolization  involves  a  hepatic  intra-arterial  injec-
ion  of  non-degradable  microspheres  bound  to 90yttrium,
hich  is  a    emitting  isotope.  The  microspheres  remain
rapped  in  the  tumor  and  are  unable  to  pass  through  the
epatic  vascular  system  and  deliver  irradiation  with  an
verage  penetration  of  2.5  mm  into  tissues  (maximum  1  cm).
he  dose  delivered  to  the  tissue  is  over  120  Gy  [70,71]  and
oes  not  cause  major  toxicity  to  the  normal  liver  which  has
imited  tolerance  to  ionizing  irradiation  (in  the  region  of
5  Gy  [72]).  Two  types  of 90yttrium  microspheres  are  avail-
ble:  glass,  which  have  been  approved  since  1999  to  treat
epatocellular  carcinoma  and  resin  microspheres  approved
y  the  FDA  in  2002  to  treat  hepatic  metastases  from
olorectal  cancer.  Two  vascular  procedures  are  needed  for
his  treatment:  The  ﬁrst  ‘‘skeletilizes’’  the  hepatic  artery
y  occluding  extra-hepatic  blood  vessels  to  non-target
rgans  (gastrointestinal  tract,  skin,  lung  and  gallbladder).
uring  this  initial  procedure  the  future  distribution  of  the
0yttrium  microspheres  is  modeled  by  scintigraphic  imaging
fter  injecting  macro-aggregates  of 99technecium-labeled
lbumin.  A  few  days  later  the 90yttrium  microspheres  are
njected  in  a  second  procedure  after  the  dose  has  been
alculated  according  to  the  distribution  of  the  injection  of
acro-aggregates  of  albumin  labeled  with 99technecium.
Radioembolization  has  been  studied  as  an  early  line  of
reatment  in  a  randomized  phase  III  study  which  compared
adioembolization  combined  with  HIAC  with  FUDR  com-
ared  to  HIAC  with  FUDR  alone  and  included  70  patients
ith  bilobar,  inoperable  metastases  from  colorectal  can-
er,  and  60  of  whom  were  previously  untreated  with
hemotherapy.  The  objective  response  rate  and  medium
ime  to  progression  of  disease  were  signiﬁcantly  longer
n  the  FUDR  plus  radioembolization  group,  with  ﬁgures  of
4%  compared  to  17.6%  and  15.9  compared  to  9.7  months
espectively  [73].  At  least  three  prospective  studies  have
xamined  the  role  of  radioembolization  combined  with  sys-
emic  chemotherapy  [74].  Used  ﬁrst  line,  radioembolization
ombined  with  systemic  5-FU  was  compared  to  systemic
-FU  alone  and  demonstrated  signiﬁcant  increases  in  the
bjective  response  rate  (73%  compared  to  0%),  time  to  pro-
ression  (18.6  compared  to  3.6  months),  progression-free
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survival  (11.5  compared  to  4.6  months)  and  overall  sur-
vival  (29.4  compared  to  12.8  months)  [75].  Prospective
studies  have  assessed  RE  in  combination  with  more  recent
chemotherapy  including  FOLFOX4  in  the  ﬁrst  line  treatment
of  25  patients  and  reported  a  90%  objective  response  rate
[76],  or  with  irinotecan  in  25  patients  who  were  previously
untreated  with  the  drug  and  had  failed  previous  chemother-
apy  and  reported  48%  objective  response  and  39%  stable
disease  rates  [77].
In  more  advanced  lines  of  therapy,  one  prospective,  mul-
ticenter,  phase  II  study  included  50  patients  with  isolated
or  predominantly  liver  metastases  who  had  progressive  pro-
gression  after  at  least  three  lines  of  systemic  chemotherapy
including  oxaliplatin  and  irinotecan.  The  disease  control
rate  was  24%  with  a  PFS  of  3.7  months,  median  survival  of
12.6  months  and  1-  and  2-year  survival  rates  of  50.4  and
19.6%  respectively  [78].  Another,  prospective,  randomized
multicenter  phase  III  study  in  46  inoperable  patients  who
were  refractory  to  chemotherapy  compared  systemic  5-FU
to  5-FU  plus  radioembolization  [79]  and  found  a  signiﬁcantly
longer  median  time  to  liver  progression  in  the  combination
group  (5.5  compared  to  2.1  months  respectively),  with  no
increase  in  toxicity  in  the  radio-chemotherapy  group,  but  no
signiﬁcant  beneﬁt  in  overall  survival  (10.0  compared  to  7.3).
It  should  be  noted  that  crossover  was  permitted  in  this  study
and  that  10  patients  included  initially  in  the  chemotherapy
only  group  progressed  and  were  treated  with  radioemboliza-
tion.  Recently,  a  prospective  cohort  study  on  302  patients
suffering  from  inoperable  liver  metastases  from  colorectal
cancer  and  treated  with  radioembolization  reported  survival
of  10.5  months  and  four  predictive  indicators,  the  num-
ber  of  lines  of  chemotherapy,  tumor  volume,  radiological
response  and  hemoglobin  concentration  [80].  A  large  ret-
rospective  comparative  cohort  study  of  339  patients  with
liver  metastases  which  were  refractory  to  chemotherapy
and  were  treated  with  radioembolization  reported  a  median
overall  survival  of  12  months  which  was  signiﬁcantly  longer
than  the  6.3  months  in  a  control  group  of  51  patients  who
did  not  undergo  radioembolization  and  were  treated  with
standard  therapy  [81].
The  side  effects  of  radioembolization  mostly  occurred
during  the  ﬁrst  week  after  treatment  and  involved  moder-
ate  abdominal  pain,  fever,  nausea  and  hepatic  dysfunction.
Most  of  the  serious  adverse  events  are  associated  with
injection  of  the 90yttrium  microspheres  into  extra-hepatic
branches  of  vessels  and  include  gastritis  or  radiation  ulcer
(5—10%),  radiation  pancreatitis  (<1%)  and  cholecystitis  (<1%)
and  are  usually  avoided  by  good  preparation  of  the  arte-
rial  bed  [74].  The  most  serious  and  relatively  unpredictable
complication  is  radiation-induced  liver  disease  due  to  the
direct  toxicity  of  the  irradiation  on  the  non-malignant  liver.
This  rare  complication  affects  approximately  4%  of  patients,
occurs  late,  from  4—8  weeks  after  radioembolization  and  is
characterized  histologically  by  sinusoidal  obstruction.  The
clinical  features  are  jaundices,  ascites  and  hepatocellular
failure  [82,83]  and  the  predictive  factors  are  bilobar  treat-
ments,  large  tumor  volume,  high  radiation  dose,  previous
chemotherapies  and  pretreatment  liver  proﬁle  abnormali-
ties.
At present,  outside  of  the  prospective  studies,  the
main  role  of  RE  is  as  a  ‘‘salvage’’  therapy  and  it  has  some
beneﬁt  and  advantages  in  disease  which  is  refractory  to
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hemotherapy  when  the  liver  tumor  burden  is  >25%,  two  or
ore  lines  of  chemotherapy  have  failed  or  the  CEA  level  is
reatly  raised  [84]. Radioembolization  is  now  recommended
n  the  ESMO  guidelines  for  patients  suffering  from  limited
iver  disease  [85].  Results  from  the  large  prospective  trials
ncluding  SIRFLOX  [86]  and  the  worldwide  FOXFIRE  [87]  are
xpected  shortly  and  should  establish  the  role  of  renewable
nergies  in  the  treatment  of  liver  metastases  of  colorectal
ancer  in  early  lines  of  therapy.
onclusion and future trends
he  treatment  of  colorectal  liver  metastases  is  now
ultimodal  and  includes  surgery,  chemotherapy  and  percu-
aneous  ablation.  Percutaneous  ablation  is  a recent  therapy
nd  offers  an  additional  curative  treatment  option  for  inop-
rable  metastases  or  for  patients  who  are  not  candidates  for
urgery.
Percutaneous  ablation  has  been  shown  to  offer  equiva-
ent  local  efﬁcacy  to  surgery  in  both  liver  and  lung,  is  far  less
nvasive  and  spares  the  parenchyma  in  selected  patients,
articularly  in  terms  of  tumor  size.  Candidates  for  surgery
ith  1  to  3  metastases  under  2—3  cm  in  size  which  are  fully
isible  and  can  be  targeted  on  imaging  should  be  discussed
n  an  MDT  to  consider  percutaneous  ablation  for  either  lung
r  liver,  possibly  in  the  same  session.  Because  of  the  limi-
ations  and  the  contraindications  of  percutaneous  ablation,
he  proportion  of  patients  who  can  actually  receive  the
echnique  is  small  compared  to  the  initial  number  of  poten-
ial  candidates.  Clearly,  pre-ablation  imaging  should  be  the
ame  as  a  pre-surgical  assessment  including  a minimum  of
hest,  abdominal  and  pelvic  CT  and  ideally  PET-CT,  which
as  been  shown  to  change  the  treatment  plan  in  26%  of
atients  intended  for  percutaneous  ablation  [88].  Increased
maging  sensitivity  in  the  future  should  allow  an  increasingly
xhaustive  assessment  of  the  disease  avoiding  preoperative
iscoveries  and  increasing  the  role  of  percutaneous  ablation
or  small  paucimetastastic  tumors.  Prognostic  indicators
nd  scores  for  both  liver  [22]  and  lung  [37]  will  help  to  select
atients  liable  to  beneﬁt  from  percutaneous  treatment
lone  and  those  who  are  potential  candidates  for  ablation
reatment  combined  with  neoadjuvant  or  adjuvant  therapy
ecause  of  a  high  risk  of  recurrence.  Advances  in  molecular
iology  will  help  to  better  deﬁne  individualized  strategies
nd  the  possibility  of  carrying  out  a  biopsy  at  the  time  of
ercutaneous  ablation  will  need  to  be  used  more  widely  for
his  purpose.  The  undisputed  advantages  of  percutaneous
blation  are  that  it  is  minimally  invasive,  and  carries  a  low
orbidity,  properties  which  should  be  capitalized  on  in  the
uture  to  enable  sequential  or  combined  treatments  with
ystemic  chemotherapy,  targeted  therapy  or  immunother-
py.  Although  ablation  is  primarily  used  at  present  as  an
ndependent  technique,  with  the  main  aim  of  completely
estroying  tumor  cells  in  the  target  volume,  combination
reatment  strategies  remain  to  be  designed  and  assessed
o  reduce  both  the  local  and  remote  recurrence  of  the
umor.  As  an  example,  an  increase  in  ablation  volume  and
fﬁcacy  has  been  demonstrated  in  animals  pre-treated  with
orafenib  [89]  and  percutaneous  ablation  produces  rises
n  plasma  IL-6  of  up  to  54  times  normal  values  [90]  which
ould  be  used  beneﬁcially  to  optimize  the  immunotherapy
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reatments  which  are  currently  being  developed  for
ancer.
If  patients  are  not  initially  candidates  for  surgery  or
blation,  hepatic  intra-arterial  chemotherapy  achieves  good
esponse  rates,  in  turn  contributing  to  high  subsequent
urgical  excision  or  percutaneous  ablation  response  rates.
he  feasibility  of  hepatic  intra-arterial  chemotherapy  is
ontinually  improving  and  percutaneous  catheter/chamber
mplantation  is  avoiding  the  need  for  surgery.  TACE  (tran-
catheter  arterial  embolization)  and  radioembolization  are
till  currently  salvage  therapies  pending  the  results  of  large
tudies  [86].
Take-home  messages
• Percutaneous  destruction  of  liver  and  lung
metastases  under  2  to  3  cm  in  size  is  over  90%.
• Overall  survival  rates  after  radiofrequency  ablation
of  lung  metastases  are  similar  to  those  obtained  after
surgical  metastasectomy.
• Hepatic  intra-arterial  chemotherapy  for  colorectal
metastases  achieves  response  rates  in  the  region  of
90%  and  surgical  conversion  rates  of  over  40%.
• Radioembolization  is  currently  recommended  by
ESMO  as  a  salvage  therapy  for  colorectal  metastases
with  limited  invasion.
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